Akorn Pharmaceuticals, a generic and brand drug manufacturer, is giving 340B covered entities refunds for overcharges on 24 NDCs from Jan. 1, 2019, through Dec. 31, 2021.
The U.S. Health Resources and Services Administration (HRSA) posted Akorn’s notice to
…